ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
19.473,63
1,32%
S&P 500
5.738,11
-0,13%
Dow Jones
42.313,13
0,33%
Euro vs US Dollar
1,11654
-0,09%
Bitcoin
65.713,30
0,81%
Registration Strip Icon for monitor Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Daxor Corporation (DXR)

  7. Daxor Corporation (DXR) News

DXR

Daxor (DXR)

Daxor Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:DXR
DatumZeitQuelleÜberschriftSymbolFirma
19/09/202414h00GlobeNewswire Inc.Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024NASDAQ:DXRDaxor Corporation
12/09/202414h00GlobeNewswire Inc.Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome ManagementNASDAQ:DXRDaxor Corporation
05/09/202414h00GlobeNewswire Inc.Daxor Corporation Receives $300K Matching Fund Award From Launch TennesseeNASDAQ:DXRDaxor Corporation
04/09/202414h30GlobeNewswire Inc.Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient CareNASDAQ:DXRDaxor Corporation
03/09/202422h05GlobeNewswire Inc.Daxor Corporation CEO and President Michael Feldschuh Delivers Corporate Update in Shareholder LetterNASDAQ:DXRDaxor Corporation
03/09/202418h15GlobeNewswire Inc.Daxor Corporation to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceNASDAQ:DXRDaxor Corporation
29/08/202423h27Edgar (US Regulatory)Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)NASDAQ:DXRDaxor Corporation
29/08/202423h16Edgar (US Regulatory)Form N-CSRS - Certified Shareholder Report, Semi-AnnualNASDAQ:DXRDaxor Corporation
29/08/202414h00GlobeNewswire Inc.Daxor Corporation Announces Launch of BVA Program at Mid-South Largest Integrated NetworkNASDAQ:DXRDaxor Corporation
23/08/202422h52Edgar (US Regulatory)Form 40-17G - Fidelity Bond [Rule 17G-1(g)]NASDAQ:DXRDaxor Corporation
16/08/202423h23Edgar (US Regulatory)Form N-2 - Registration statement for closed-end investment companiesNASDAQ:DXRDaxor Corporation
06/08/202414h00GlobeNewswire Inc.Daxor Corporation Awarded $1.9M Contract by The U.S. Air Force for Development of its Next Generation Tracer System in its Point-of-Care Blood Volume AnalyzerNASDAQ:DXRDaxor Corporation
05/08/202414h00GlobeNewswire Inc.Daxor Expands To Three New Facilities As Blood Volume Analysis Technology Gains Momentum NationwideNASDAQ:DXRDaxor Corporation
24/07/202414h00GlobeNewswire Inc.Daxor Corporation Awarded New U.S. Defense Health Agency Contract for Added Capabilities to Its Point-of-Care Blood Volume AnalyzerNASDAQ:DXRDaxor Corporation
18/07/202420h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DXRDaxor Corporation
18/07/202400h01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
17/07/202423h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
17/07/202423h50Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
17/07/202423h46Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DXRDaxor Corporation
11/07/202414h00GlobeNewswire Inc.Daxor Corporation’s BVA-100™ Blood Volume Diagnostic Expands to Three New Centers, Gains Traction NationwideNASDAQ:DXRDaxor Corporation
18/06/202414h00GlobeNewswire Inc.Daxor Corporation to Showcase the Benefits of BVA-100™ Guided-Care at the American Association of Heart Failure Nurses (AAHFN) 20th Annual MeetingNASDAQ:DXRDaxor Corporation
05/06/202422h10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DXRDaxor Corporation
05/06/202414h00GlobeNewswire Inc.Daxor Corporation Appoints John L. Jefferies, M.D. as Chief Medical OfficerNASDAQ:DXRDaxor Corporation
30/05/202412h43Edgar (US Regulatory)Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public)NASDAQ:DXRDaxor Corporation
16/04/202414h00GlobeNewswire Inc.New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of CongestionNASDAQ:DXRDaxor Corporation
15/04/202414h00GlobeNewswire Inc.DAXOR CORPORATION TO EXHIBIT AT THE MEDAXIOM CARDIOVASCULAR TRANSFORUM CONFERENCE SPRING’24 TO ADVANCE AWARENESS AND FURTHER ADOPTION OF DAXOR’S BLOOD VOLUME DIAGNOSTIC (BVA-100™)NASDAQ:DXRDaxor Corporation
10/04/202414h00GlobeNewswire Inc.Daxor Corporation Announces New Hospital Account at Leading Chicago HospitalNASDAQ:DXRDaxor Corporation
01/04/202414h00GlobeNewswire Inc.Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24NASDAQ:DXRDaxor Corporation
25/03/202413h00GlobeNewswire Inc.Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of DiagnosticsNASDAQ:DXRDaxor Corporation
22/03/202413h00GlobeNewswire Inc.Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024NASDAQ:DXRDaxor Corporation
 Showing the most relevant articles for your search:NASDAQ:DXR

Kürzlich von Ihnen besucht

COIN
SMPTGBP
Smart Pharma Token
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten